Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Background: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. Objectives: The main objectives of the study were to establish the clinical effect...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Thomas RE Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
Format: Artigo
Langue:Inglês
Publié: NIHR Journals Library 2017-09-01
Collection:Health Technology Assessment
Sujets:
amisulpride
clozapine
schizophrenia
treatment-resistant schizophrenia
randomised controlled trial
placebo controlled
cost-effectiveness
Accès en ligne:https://doi.org/10.3310/hta21490
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires